FDA Grants Limited Approval for Moderna’s Lower-Dose COVID Vaccine

The U.S. Food and Drug Administration (FDA) has issued a limited approval for a new lower-dose COVID vaccine developed by Moderna. The company announced the approval this weekend, highlighting that the new vaccine formulation is aimed at older adults and young people with underlying medical conditions that increase their risk of severe COVID-19.

The approval, which was granted by the FDA on Friday, is specifically for individuals who have previously received a COVID vaccine. Moderna’s latest offering contains just one-fifth of the original dose used in the company’s initial COVID vaccine rollout. According to Moderna, the new vaccine was tested in a trial of more than 11,000 participants aged 12 and older.

The trial results were promising, with the new vaccine generating higher antibody levels than the company’s original COVID shot. These findings are encouraging for high-risk populations who may require additional protection against severe outcomes from the virus.

The approval comes at a time when public health agencies are continuing to monitor COVID-19 variants and explore ways to protect the most vulnerable populations. The limited approval underscores the ongoing need for targeted vaccination strategies, especially for those with compromised immune systems or pre-existing health conditions.

Moderna’s lower-dose vaccine is expected to be available soon for eligible groups, though the company has not yet announced a specific timeline for distribution.

For more updates on COVID-19 developments and other health news, visit nbcpalmsprings.com or follow NBC Palm Springs on social media.

Explore: NBCPalmSprings.com, where we are connecting the Valley.